Carrera-Cañas Carlos, de Andrés Isabel, Callejo Marta, Garzón Miguel
Departamento de Anatomía, Histología y Neurociencia, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain.
Front Mol Neurosci. 2022 Oct 5;15:1013182. doi: 10.3389/fnmol.2022.1013182. eCollection 2022.
The hypothalamic hypocretinergic/orexinergic (Hcrt/Ox) system is involved in many physiological and pathophysiological processes. Malfunction of Hcrt/Ox transmission results in narcolepsy, a sleep disease caused in humans by progressive neurodegeneration of hypothalamic neurons containing Hcrt/Ox. To explore the Hcrt/Ox system plasticity we systemically administered suvorexant (a dual Hcrt/Ox receptor antagonist) in rats to chronically block Hcrt/Ox transmission without damaging Hcrt/Ox cells. Three groups of eight rats (four males and four females) received daily i.p. injections of suvorexant (10 or 30 mg/kg) or vehicle (DMSO) over a period of 7 days in which the body weight was monitored. After the treatments cerebrospinal fluid (CSF) Hcrt1/OxA concentration was measured by ELISA, and hypothalamic Hcrt/OxR1 and Hcrt/OxR2 levels by western blot. The systemic blockade of the Hcrt/Ox transmission with the suvorexant high dose produced a significant increase in body weight at the end of the treatment, and a significant decrease in CSF Hcrt1/OxA levels, both features typical in human narcolepsy type 1. Besides, a significant overexpression of hypothalamic Hcrt/OxR1 occurred. For the Hcrt/OxR2 two very close bands were detected, but they did not show significant changes with the treatment. Thus, the plastic changes observed in the Hcrt/Ox system after the chronic blockade of its transmission were a decrease in CSF Hcrt1/OXA levels and an overexpression of hypothalamic Hcrt/OxR1. These findings support an autoregulatory role of Hcrt/OxR1 within the hypothalamus, which would induce the synthesis/release of Hcrt/Ox, but also decrease its own availability at the plasma membrane after binding Hcrt1/OxA to preserve Hcrt/Ox system homeostasis.
下丘脑分泌素能/食欲素能(Hcrt/Ox)系统参与许多生理和病理生理过程。Hcrt/Ox传递功能障碍会导致发作性睡病,这是一种在人类中由含Hcrt/Ox的下丘脑神经元进行性神经变性引起的睡眠疾病。为了探究Hcrt/Ox系统的可塑性,我们对大鼠系统性给予苏沃雷生(一种双重Hcrt/Ox受体拮抗剂),以长期阻断Hcrt/Ox传递而不损伤Hcrt/Ox细胞。三组,每组八只大鼠(四只雄性和四只雌性)在7天内每天腹腔注射苏沃雷生(10或30mg/kg)或溶剂(二甲基亚砜),在此期间监测体重。治疗后,通过酶联免疫吸附测定法测量脑脊液(CSF)中Hcrt1/OxA浓度,通过蛋白质免疫印迹法测量下丘脑Hcrt/OxR1和Hcrt/OxR2水平。用高剂量苏沃雷生系统性阻断Hcrt/Ox传递在治疗结束时导致体重显著增加,以及CSF中Hcrt1/OxA水平显著降低,这两个特征都是1型人类发作性睡病的典型特征。此外,下丘脑Hcrt/OxR1出现显著过表达。对于Hcrt/OxR2,检测到两条非常接近的条带,但它们在治疗后未显示出显著变化。因此,在长期阻断Hcrt/Ox传递后,在Hcrt/Ox系统中观察到的可塑性变化是CSF中Hcrt1/OXA水平降低和下丘脑Hcrt/OxR1过表达。这些发现支持Hcrt/OxR1在下丘脑中的自调节作用,这将诱导Hcrt/Ox的合成/释放,但在Hcrt1/OxA结合后也会降低其自身在质膜上的可用性,以维持Hcrt/Ox系统的稳态。